Condition deep-dive · 7 min read

Multiple sclerosis adjunct — what supplements add to disease-modifying therapy

Updated 2026-05-15 · Reviewed by SupplementScore editors · No sponsorships

Multiple sclerosis (MS) is an autoimmune-mediated demyelinating disease where the main clinical lever is disease-modifying therapy (interferons, glatiramer, fingolimod, dimethyl fumarate, teriflunomide, S1P modulators, ocrelizumab, ofatumumab, natalizumab, cladribine, autologous HSCT in selected cases). The supplement layer is genuinely adjunctive: vitamin D has the strongest population and trial evidence; omega-3 and alpha-lipoic acid have mechanism and small-trial support; high-dose biotin was a promising lead until the SPI2 trial in 2020 was negative; the rest is mostly hopeful and unproven. The honest read: supplements may help fatigue, symptom burden, and possibly relapse rate; they do not replace DMT in any modern MS protocol.

MS care is neurology-led; supplements are never first-line. Disease-modifying therapy reduces relapse rate, disability accumulation, and brain volume loss in ways no supplement has replicated. Stopping or refusing DMT in favour of supplements has measurable adverse consequences. The supplement layer fits alongside neurologist-prescribed DMT, not instead of it. Discuss every supplement with your MS team — particularly the immunomodulators (echinacea, andrographis, mistletoe) that can interact with DMT.

What actually has trial evidence

Tier 1 evidence · Strongest supplement signal in MS

Vitamin D3

2,000–5,000 IU/day to a 25-OH-D target of 40–60 ng/mL (100–150 nmol/L)

Low vitamin D status is associated with MS risk, relapse rate, and MRI lesion activity in observational and Mendelian-randomisation studies. The SOLAR and EVIDIMS trials of high-dose D as add-on to DMT had mixed primary endpoints but consistent direction on MRI activity and relapse rate. Endorsed by most MS specialists as standard adjunct, with target 25-OH-D 40–60 ng/mL (higher than the general-population sufficiency threshold). Avoid mega-doses (>10,000 IU/day chronically) without measurement; hypercalcaemia is the safety endpoint.

Tier 2 evidence · Anti-inflammatory adjunct

Omega-3 EPA/DHA

2–4 g EPA+DHA/day

The OFAMS trial (Torkildsen 2012) showed modest reductions in disease activity with omega-3 + interferon vs interferon alone, though primary endpoint was not robustly met. Meta-analyses of omega-3 in MS show modest effects on relapse rate and fatigue. Plausible mechanism via resolvin/protectin-mediated reduction of neuroinflammation. Reasonable adjunct given the safety profile. Discuss with prescriber if on anticoagulants.

Tier 2 evidence · Brain volume signal in progressive MS

Alpha-lipoic acid (ALA)

1,200 mg/day oral, divided

The Spain 2017 RCT (n=51 secondary progressive MS, 2 years) found ALA 1,200 mg/day reduced brain atrophy rate by approximately 68% vs placebo — a striking result that warrants replication. Mechanism: mitochondrial antioxidant activity, reduction of oxidative stress in chronically demyelinated axons. The trial was small; larger replication is in progress. Reasonable adjunct in progressive MS pending more data.

Tier 2 evidence · Deficiency-corrective

Vitamin B12 (methylcobalamin if deficient)

1,000 mcg/day methylcobalamin oral, or IM if deficient

B12 deficiency overlaps with MS clinically (paresthesia, cognitive symptoms, optic neuritis, subacute combined degeneration). Test serum B12 and methylmalonic acid; treat to clear deficiency. Some specialists target higher B12 levels in MS for neurological repair support, though trial evidence for high-dose B12 in B12-replete patients is absent.

Tier 3 evidence · Fatigue endpoint

CoQ10 (ubiquinol form)

200–500 mg/day

Small trials (Sanoobar 2013, 2016) showed CoQ10 200–500 mg/day reduced MS-related fatigue and inflammatory markers. Mitochondrial dysfunction is a feature of chronically demyelinated MS lesions. Reasonable adjunct particularly for fatigue-prominent MS; effect sizes modest.

Tier 4 evidence · Negative pivotal trial

High-dose biotin (300 mg/day) — NOT recommended

N/A — SPI2 trial was negative

The MD1003 high-dose biotin protocol (300 mg/day) showed promise in early progressive MS trials (Sedel 2015). The SPI2 phase 3 trial (Cree 2020, n=642) was negative on the primary disability-improvement endpoint. High-dose biotin also distorts laboratory immunoassays (TSH, troponin, hormone tests), causing diagnostic errors. The signal did not replicate. Do not start; if already on, discuss discontinuation with your neurologist.

The lifestyle and behavioural base — high-yield in MS

Smoking cessation — among the highest-yield interventions in MS; smoking accelerates progression and increases relapse risk.
Aerobic and resistance exercise — evidence-graded improvements in fatigue, gait, mood, and possibly disability accumulation. Adapted to disability level.
Sleep hygiene and screening for OSA — MS fatigue often has a sleep-disordered-breathing component; treat OSA if present.
Mediterranean dietary pattern (or "Wahls / OMS" variants with caveats) — Mediterranean has the largest observational base; the Wahls and OMS popular protocols have small open-label data but no rigorous RCT support — choose a sustainable, plant-rich, low-saturated-fat pattern.
Heat management — Uhthoff phenomenon: heat worsens MS symptoms; cooling vests, air conditioning, and cooler-shower routines reduce daily symptom burden.
Vaccinations — annual influenza, COVID, and other indicated vaccines reduce infection-driven relapses. Live vaccines need DMT-specific guidance.
Mental health care — depression prevalence in MS is ~50%; treat actively. CBT, SSRIs, and exercise all have evidence.
Bladder, bowel, and spasticity care — symptomatic management is its own large topic, beyond the supplement layer.

What to skip

High-dose biotin (300 mg/day) — SPI2 trial was negative; assay-interference risks remain.
Echinacea, andrographis, mistletoe, immune-stimulating botanicals — theoretical concern about flaring autoimmunity; the wrong immunomodulator class.
"Adrenal fatigue" stacks with ashwagandha + licorice — adrenal fatigue is not a recognised entity; ashwagandha has thyroid effects that complicate MS-related fatigue assessment.
Stem cell tourism and "regenerative" infusion clinics — autologous HSCT under neurology supervision is a legitimate option in selected patients; commercial stem cell tourism is not.
Mega-dose vitamin E, vitamin A — no MS benefit; high-dose A is hepatotoxic.
Bee venom / apitoxin therapy — well-conducted trials negative; carries serious adverse-event risk.
"Heavy metal detox" or chelation — no MS evidence; chelation has its own toxicity risks.
Replacing DMT with supplements — this is the most important "don't" in this list.

What to track

Track in collaboration with your MS team: annual MRI (new T2 lesions, gadolinium-enhancing lesions, brain volume), Expanded Disability Status Scale (EDSS) at neurology visits, MSIS-29 or MSIQOL-54 patient-reported outcome at intervals, 25-OH-D every 3–6 months until target reached then yearly, and CBC/LFTs as required by your DMT. Fatigue measured with Modified Fatigue Impact Scale (MFIS) or Fatigue Severity Scale.

Practical quick-start. Stay on your DMT — this is the foundation. Optimise vitamin D to 40–60 ng/mL with 2,000–5,000 IU/day D3 alongside K2 MK-7. Add omega-3 EPA+DHA 2 g/day. Smoking cessation. Mediterranean dietary pattern. Aerobic + resistance exercise. Treat sleep disorders. Screen and treat depression. Test B12 / methylmalonic acid — supplement on deficiency. Consider ALA 1,200 mg/day in progressive MS pending replication of Spain trial. Do not start high-dose biotin. Coordinate every supplement decision with your MS team — particularly DMT interactions.

Sources

Hupperts R, et al. Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a (SOLAR). Neurology. 2019;93(20):e1906–e1916. PMID: 31594857
Spain R, et al. Lipoic acid in secondary progressive MS: a randomized controlled pilot trial. Neurol Neuroimmunol Neuroinflamm. 2017;4(5):e374. PMID: 28680916
Torkildsen O, et al. ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Arch Neurol. 2012;69(8):1044–1051. PMID: 22507886
Cree BAC, et al. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2). Lancet Neurol. 2020;19(12):988–997. PMID: 33222769
Sanoobar M, et al. Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with relapsing-remitting multiple sclerosis. Int J Neurosci. 2013;123(11):776–782. PMID: 23659338
Sintzel MB, et al. Vitamin D and multiple sclerosis: a comprehensive review. Neurol Ther. 2018;7(1):59–85. PMID: 29243029